Gene:
ESR1
estrogen receptor 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB annotates drug labels containing pharmacogenetic information approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency, Japan (PMDA). PharmGKB annotations provide a brief summary of the PGx in the label, an excerpt from the label and a downloadable highlighted label PDF file. A list of genes and phenotypes found within the label is mapped to label section headers and listed at the end of each annotation. PharmGKB also attempts to interpret the level of action implied in each label with the "PGx Level" tag.

Sources:

  • FDA Information is gathered from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" and from FDA-approved labels brought to our attention. Please note that drugs may be removed from or added to the FDA's Table without our knowledge. We periodically check the Table for changes and update PharmGKB accordingly. Drugs listed on the Table to our knowledge are tagged with the Biomarker icon. A drug label that has been removed from the Table will not have the Biomarker icon but will continue to have an annotation on PharmGKB stating the label has been removed from the FDA's Table. We acquire label PDF files from DailyMed.
  • EMA European Public Assessment Reports (EPARs) that contain PGx information were identified from [Article:24433361] and also by searching for drugs for which we have PGx-containing FDA drug labels.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA, PMDA or other Medicine Agencies around the world - please contact feedback.



last updated 12/16/2013

FDA Label for anastrozole and ESR1, ESR2, PGR

Genetic testing required

Summary

Anastrozole (ARIMIDEX) is an aromatase inhibitor indicated for use in postmenopausal women as an adjuvant treatment for hormone receptor-positive early breast cancer, as a first-line treatment for hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer, or to treat advanced breast cancer with disease progression following tamoxifen therapy.

There's more of this label. Read more.


last updated 12/17/2013

FDA Label for everolimus and ERBB2, ESR1

Genetic testing required

Summary

Everolimus (AFINITOR) is indicated for treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. It is also indicated for adults with neuroendocrine tumors of pancreatic origin or advanced renal cell carcinoma.

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for exemestane and ESR1, ESR2

Genetic testing required

Summary

Aromasin is an aromatase inhibitor indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen.

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for fulvestrant and ESR1, ESR2

Genetic testing required

Summary

Fulvestrant is used to treat hormone-receptor positive breast cancer in postmenopausal women whose disease has spread after treatment with an antiestrogen medicine.

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for letrozole and ESR1, PGR

Genetic testing required

Summary

Letrozole (Femara) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. It is also indicated as a first-line treatment for advanced breast cancer in postmenopausal women with hormone receptor positive or unknown tumors, or for extended adjuvant treatment of post-menopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.

There's more of this label. Read more.


last updated 01/16/2014

FDA Label for tamoxifen and ESR1, ESR2, F2, F5

Actionable PGx

Summary

Tamoxifen is an anti-estrogen used in the treatment and prevention of breast neoplasms particularly those with estrogen receptor positive breast cancer.

There's more of this label. Read more.




PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all ESR1 variant annotations

Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs2077647 122447T>C, 152129077T>C, 30T>C, 56298534T>C, ESR1:S10S, ESR1:T29C, ESR1:T30C, ESR1:rs2077647, Ser10=
T > C
Synonymous
Ser10Ser
No VIP available CA VA
rs2207396 1369+123G>A, 152382382G>A, 375752G>A, 56551839G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs2228480 152420095G>A, 1782G>A, 413465G>A, 56589552G>A, ESR1:1782G>A, ESR1:BtgI, ESR1:G2014A, ESR1:G594A, ESR1:rs2228480, T594T, Thr594=
G > A
Synonymous
Thr594Thr
No VIP available CA VA
rs2234693 152163335T>C, 156705T>C, 453-397T>C, 56332792T>C, ESR1:PvuII, ESR1:c.454-397T>C, ESR1:rs2234693
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs3020314 1096+5029C>T, 152270672C>T, 264042C>T, 56440129C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs3798577 *1029T>C, 152421130T>C, 414500T>C, 56590587T>C, ESR1:rs3798577
T > C
3' UTR
No VIP available No Clinical Annotations available VA
rs9322336 152200430C>T, 193800C>T, 56369887C>T, 644-1360C>T
C > T
Intronic
No VIP available CA VA
rs9340799 152163381A>G, 156751A>G, 453-351A>G, 56332838A>G, ESR1:XbaI, ESR1:c.454-351A>G, ESR1:rs9340799
A > G
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142

Overview

Alternate Names:  ESR
Alternate Symbols:  Era; NR3A1
PharmGKB Accession Id: PA156

Details

Cytogenetic Location: chr6 : q25.1 - q25.1
GP mRNA Boundary: chr6 : 152011631 - 152424409
GP Gene Boundary: chr6 : 152001631 - 152427409
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics
    Summary of pathways of estrogens and antiestrogens.

External Pathways

Links to non-PharmGKB pathways.

  1. carm1 and regulation of the estrogen receptor - (BioCarta via Pathway Interaction Database)
  2. downregulated of mta-3 in er-negative breast tumors - (BioCarta via Pathway Interaction Database)
  3. estrogen responsive protein efp controls cell cycle and breast tumors growth - (BioCarta via Pathway Interaction Database)
  4. FOXA1 transcription factor network - (Pathway Interaction Database NCI-Nature Curated)
  5. FOXM1 transcription factor network - (Pathway Interaction Database NCI-Nature Curated)
  6. overview of telomerase protein component gene htert transcriptional regulation - (BioCarta via Pathway Interaction Database)
  7. pelp1 modulation of estrogen receptor activity - (BioCarta via Pathway Interaction Database)
  8. Plasma membrane estrogen receptor signaling - (Pathway Interaction Database NCI-Nature Curated)
  9. Regulation of nuclear SMAD2/3 signaling - (Pathway Interaction Database NCI-Nature Curated)
  10. Regulation of Telomerase - (Pathway Interaction Database NCI-Nature Curated)
  11. role of erbb2 in signal transduction and oncology - (BioCarta via Pathway Interaction Database)
  12. Signaling events mediated by HDAC Class II - (Pathway Interaction Database NCI-Nature Curated)
  13. Signaling mediated by p38-alpha and p38-beta - (Pathway Interaction Database NCI-Nature Curated)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT2B10
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT2B15
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT2B7

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Alkylating Agents

Curated Information ?

Publications related to ESR1: 53

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic Factors Affecting Gene Transcription and Catalytic Activity of UDP-Glucuronosyltransferases in Human Liver. Human molecular genetics. 2014. Liu Wanqing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nature genetics. 2013. Robinson Dan R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature genetics. 2013. Toy Weiyi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects. British journal of cancer. 2013. Henry N L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association study of the estrogen receptor gene ESR1 with postpartum depression-a pilot study. Archives of women's mental health. 2013. Pinsonneault Julia K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast cancer research and treatment. 2013. Henry N Lynn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The future of pharmacogenetics for osteoporosis. Pharmacogenomics. 2013. Marini Francesca, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. PLoS biology. 2012. Kalyuga Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. PloS one. 2013. McDonough Caitrin W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer. PloS one. 2013. Wang Jingxuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes. Frontiers in pharmacology. 2012. Philips Santosh, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Estrogen receptor alpha single nucleotide polymorphism modifies the risk of azoospermia in childhood cancer survivors. Pharmacogenetics and genomics. 2011. Romerius Patrik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. The American journal of psychiatry. 2011. Greenwood Tiffany A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics. 2011. Dziedziejko Violetta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacological reports : PR. 2011. Baer-Dubowska Wanda, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clinical pharmacology and therapeutics. 2010. Hayes D F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of osteoporosis-related bone fractures: moving towards the harmonization and validation of polymorphism diagnostic tools. Pharmacogenomics. 2010. Rojo Venegas Karen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism & related disorders. 2010. Palacios N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adenosine A1 receptor, a target and regulator of estrogen receptoralpha action, mediates the proliferative effects of estradiol in breast cancer. Oncogene. 2010. Lin Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. British journal of cancer. 2010. Henry N L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagnostic pathology. 2010. Gul Aylin Ege, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of EGFR and HER2 polymorphisms with risk and clinical features of thyroid cancer. Genetic testing and molecular biomarkers. 2009. Rebaï Maha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PloS one. 2010. Nencioni Alessio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Annals of internal medicine. 2009. Richards J Brent, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A functional polymorphism in estrogen receptor alpha gene is associated with Japanese methamphetamine induced psychosis. Progress in neuro-psychopharmacology & biological psychiatry. 2009. Kishi Taro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast cancer research and treatment. 2009. Onitilo Adedayo A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Associations of the estrogen receptors 1 and 2 gene polymorphisms with the metabolic syndrome in women. Metabolic syndrome and related disorders. 2009. Goulart Alessandra C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer. Cancer research. 2008. Rokavec Matjaz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia. Journal of biomedicine & biotechnology. 2009. Kallel Imen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estrogen receptor alpha gene variants associate with type 2 diabetes and fasting plasma glucose. Pharmacogenetics and genomics. 2008. Dahlman Ingrid, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HER-2/neu Ile655Val polymorphism and the risk of breast cancer. Annals of the New York Academy of Sciences. 2008. Siddig Awatif, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008. French Deborah, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clinical pharmacology and therapeutics. 2008. Ntukidem N I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multiple genetic loci for bone mineral density and fractures. The New England journal of medicine. 2008. Styrkarsdottir Unnur, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human CYP2A6 is induced by estrogen via estrogen receptor. Drug metabolism and disposition: the biological fate of chemicals. 2007. Higashi Eriko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature genetics. 2007. Holst Frederik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature genetics. 2007. Bertram Lars, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science (New York, N.Y.). 2006. Poole Aleksandra Jovanovic, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. The Journal of biological chemistry. 2006. Yamamoto Yukio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circulation research. 2006. Shearman Amanda M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis. 2005. Kajinami Kouji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (New York, N.Y.). 2004. Egan Karine M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer research. 2004. Widschwendter Martin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast cancer research and treatment. 2004. Johnson Michael D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. Argiris Athanassios, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism of alpha-estrogen receptor and aryl hydrocarbon receptor genes in dementia patients in Shanghai suburb. Acta pharmacologica Sinica. 2003. Lin Guo-Fang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of estrogen receptor-alpha gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. Arteriosclerosis, thrombosis, and vascular biology. 2002. Lu Hong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. The New England journal of medicine. 2002. Herrington David M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vitamin D receptor and estrogen receptor gene polymorphisms in postmenopausal Danish women: no relation to bone markers or serum lipoproteins. Climacteric : the journal of the International Menopause Society. 2000. Bagger Y Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clinical endocrinology. 2000. Ongphiphadhanakul B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Human genetics. 1998. Deng H W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with ERBB2 gene amplification. European journal of cancer (Oxford, England : 1990). 1996. Wärri A M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer research. 1992. Russell K S, et al. PubMed

LinkOuts

HuGE:
ESR1
Comparative Toxicogenomics Database:
2099
ModBase:
P03372
HumanCyc Gene:
HS01746
HGNC:
3467

Common Searches